patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_209380 | REC_0009601 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 7.1 | 65 | female | 0 | 8 | 6.2 | 2 | alectinib 600 mg BID | 22.3 | false | MSS | 2026-03-15T05:35:59.229052+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_194375 | REC_0009602 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 17 | 2 | 67 | female | 0 | 26 | 5.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 19 | true | MSS | 2026-03-15T05:35:59.229289+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500447 | REC_0009603 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 15 | 56 | male | 0 | 31 | 6.3 | 4 | sotorasib 960 mg daily | 10.8 | false | MSI-H | 2026-03-15T05:35:59.229523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456041 | REC_0009604 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 19 | 9.9 | 75 | female | 1 | 29 | 4 | 0 | osimertinib 80 mg daily | 35.6 | false | MSS | 2026-03-15T05:35:59.229751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927581 | REC_0009605 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 15 | 61 | female | 0 | 7 | 4 | 1 | osimertinib 80 mg daily | 12.5 | true | MSI-H | 2026-03-15T05:35:59.229998+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533236 | REC_0009606 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 15 | 16.3 | 77 | female | 2 | 17 | 7.1 | 1 | alectinib 600 mg BID | 15.8 | true | MSS | 2026-03-15T05:35:59.230261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_134092 | REC_0009607 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 14.6 | 68 | female | 0 | 10 | 4.1 | 1 | sotorasib 960 mg daily | 25.2 | false | MSS | 2026-03-15T05:35:59.230499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_655600 | REC_0009608 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 13.2 | 70 | female | 2 | 15 | 6.6 | 8 | pembrolizumab 200 mg q3w | 10 | false | MSS | 2026-03-15T05:35:59.230781+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103429 | REC_0009609 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 10.4 | 71 | male | 2 | 14 | 3.7 | 1 | alectinib 600 mg BID | 31.8 | false | MSS | 2026-03-15T05:35:59.231017+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366388 | REC_0009610 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 14.3 | 58 | female | 1 | 18 | 7.6 | 6 | sotorasib 960 mg daily | 6.2 | false | MSS | 2026-03-15T05:35:59.231252+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_892354 | REC_0009611 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 8.5 | 70 | female | 1 | 11 | 6.1 | 6 | alectinib 600 mg BID | 8.9 | true | MSS | 2026-03-15T05:35:59.231492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554988 | REC_0009612 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 6.7 | 58 | male | 1 | 11 | 5.3 | 1 | pembrolizumab 200 mg q3w | 18.3 | false | MSS | 2026-03-15T05:35:59.231725+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633188 | REC_0009613 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 13.7 | 68 | female | 1 | 12 | 6.7 | 3 | osimertinib 80 mg daily | 5.7 | true | MSS | 2026-03-15T05:35:59.231969+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_908235 | REC_0009614 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 9 | 61 | male | 0 | 22 | 8.7 | 1 | osimertinib 80 mg daily | 14.5 | false | MSS | 2026-03-15T05:35:59.232227+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996921 | REC_0009615 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 14.7 | 66 | male | 1 | 20 | 4.9 | 7 | entrectinib 600 mg daily | 5.6 | false | MSI-H | 2026-03-15T05:35:59.232477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132608 | REC_0009616 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 14.2 | 72 | male | 1 | 13 | 5.8 | 1 | pembrolizumab 200 mg q3w | 27 | false | MSS | 2026-03-15T05:35:59.232771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_497523 | REC_0009617 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 10.6 | 70 | female | 2 | 7 | 6.4 | 1 | sotorasib 960 mg daily | 20.5 | false | MSI-H | 2026-03-15T05:35:59.233012+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420174 | REC_0009618 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 12.4 | 57 | female | 1 | 19 | 4.8 | 1 | alectinib 600 mg BID | 30.5 | true | MSI-H | 2026-03-15T05:35:59.233253+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429191 | REC_0009619 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 11 | 79 | female | 2 | 17 | 6.4 | 1 | osimertinib 80 mg daily | 26.5 | true | MSI-H | 2026-03-15T05:35:59.233493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686358 | REC_0009620 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 32 | 6 | 75 | female | 1 | 12 | 6 | 5 | pembrolizumab 200 mg q3w | 12.2 | false | MSS | 2026-03-15T05:35:59.233734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606409 | REC_0009621 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 18 | 8.4 | 66 | female | 0 | 56 | 6.3 | 7 | pembrolizumab 200 mg q3w | 8.9 | true | MSS | 2026-03-15T05:35:59.234059+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974168 | REC_0009622 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 8.2 | 77 | female | 0 | 33 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.8 | true | MSS | 2026-03-15T05:35:59.234329+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994695 | REC_0009623 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 6.7 | 58 | female | 1 | 4 | 5.9 | 2 | osimertinib 80 mg daily | 24.9 | true | MSS | 2026-03-15T05:35:59.234584+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422734 | REC_0009624 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 4.7 | 72 | female | 2 | 46 | 3.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.8 | true | MSS | 2026-03-15T05:35:59.234833+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_982244 | REC_0009625 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 6.6 | 76 | female | 1 | 12 | 4.7 | 8 | alectinib 600 mg BID | 10.9 | false | MSS | 2026-03-15T05:35:59.235077+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393407 | REC_0009626 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 14.1 | 70 | female | 0 | 14 | 6.1 | 1 | osimertinib 80 mg daily | 18.6 | false | MSI-H | 2026-03-15T05:35:59.235318+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_667424 | REC_0009627 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 16.3 | 69 | female | 0 | 19 | 6.5 | 5 | sotorasib 960 mg daily | 17.6 | true | MSS | 2026-03-15T05:35:59.235579+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_875009 | REC_0009628 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 14.4 | 74 | female | 2 | 22 | 6.7 | 5 | osimertinib 80 mg daily | 5.3 | true | MSS | 2026-03-15T05:35:59.235818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_624487 | REC_0009629 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 12.4 | 60 | female | 0 | 8 | 4.3 | 8 | sotorasib 960 mg daily | 9 | true | MSS | 2026-03-15T05:35:59.236068+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_451036 | REC_0009630 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 13 | 12.6 | 61 | male | 0 | 12 | 6.7 | 1 | osimertinib 80 mg daily | 23.9 | false | MSS | 2026-03-15T05:35:59.236459+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445752 | REC_0009631 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 16.5 | 67 | female | 1 | 16 | 7 | 5 | osimertinib 80 mg daily | 13.2 | false | MSI-H | 2026-03-15T05:35:59.236706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_443680 | REC_0009632 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 6.1 | 71 | male | 1 | 50 | 4.8 | 3 | carboplatin + paclitaxel + pembrolizumab | 9.1 | true | MSS | 2026-03-15T05:35:59.236944+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_108516 | REC_0009633 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 13 | 10.3 | 74 | female | 2 | 14 | 5.6 | 4 | osimertinib 80 mg daily | 10.5 | false | MSS | 2026-03-15T05:35:59.237181+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_178661 | REC_0009634 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 11 | 56 | female | 1 | 17 | 5.9 | 4 | entrectinib 600 mg daily | 17.6 | true | MSS | 2026-03-15T05:35:59.237534+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109615 | REC_0009635 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 19 | 16.3 | 56 | male | 0 | 25 | 5.4 | 8 | pembrolizumab 200 mg q3w | 9.4 | true | MSI-H | 2026-03-15T05:35:59.237779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_428665 | REC_0009636 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 14.2 | 67 | female | 0 | 17 | 6.5 | 7 | alectinib 600 mg BID | 9.5 | false | MSI-H | 2026-03-15T05:35:59.238011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_561485 | REC_0009637 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 8.1 | 83 | female | 1 | 30 | 6.5 | 6 | alectinib 600 mg BID | 8 | false | MSS | 2026-03-15T05:35:59.238241+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_198316 | REC_0009638 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 2.8 | 79 | male | 2 | 63 | 5.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 5.8 | false | MSS | 2026-03-15T05:35:59.238479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_586492 | REC_0009639 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 10.2 | 68 | male | 0 | 12 | 7.7 | 2 | osimertinib 80 mg daily | 16.9 | true | MSS | 2026-03-15T05:35:59.238717+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506749 | REC_0009640 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 11.8 | 77 | female | 2 | 10 | 4.5 | 1 | alectinib 600 mg BID | 14.6 | false | MSS | 2026-03-15T05:35:59.238953+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_561694 | REC_0009641 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 10.3 | 69 | female | 1 | 23 | 6.2 | 6 | sotorasib 960 mg daily | 12.7 | true | MSS | 2026-03-15T05:35:59.239182+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368546 | REC_0009642 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 9.5 | 66 | female | 0 | 28 | 5.1 | 5 | sotorasib 960 mg daily | 10.8 | false | MSS | 2026-03-15T05:35:59.239408+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309022 | REC_0009643 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 6 | 75 | male | 2 | 10 | 4.6 | 7 | osimertinib 80 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:59.239643+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_400983 | REC_0009644 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 7.5 | 70 | female | 2 | 44 | 5.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 7.1 | false | MSS | 2026-03-15T05:35:59.239867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_884742 | REC_0009645 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 7.6 | 83 | female | 2 | 17 | 6.1 | 1 | entrectinib 600 mg daily | 15.3 | true | MSS | 2026-03-15T05:35:59.240144+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548749 | REC_0009646 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 4.1 | 65 | female | 0 | 46 | 3.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.6 | false | MSS | 2026-03-15T05:35:59.240393+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_728038 | REC_0009647 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 34 | 12.9 | 76 | female | 2 | 12 | 6.4 | 4 | osimertinib 80 mg daily | 16.1 | true | MSI-H | 2026-03-15T05:35:59.240768+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_258804 | REC_0009648 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 3.9 | 60 | female | 0 | 46 | 7 | 6 | carboplatin + paclitaxel + pembrolizumab | 4.9 | true | MSS | 2026-03-15T05:35:59.241014+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_240866 | REC_0009649 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 10.9 | 60 | female | 0 | 10 | 5.5 | 6 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.241281+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_568791 | REC_0009650 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 19 | 8.3 | 67 | female | 1 | 9 | 5 | 4 | pembrolizumab 200 mg q3w | 5.7 | true | MSS | 2026-03-15T05:35:59.241559+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692961 | REC_0009651 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 7 | 77 | female | 1 | 48 | 5.4 | 7 | carboplatin + paclitaxel + pembrolizumab | 14.5 | false | MSS | 2026-03-15T05:35:59.241885+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_270999 | REC_0009652 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 19 | 13.2 | 63 | male | 1 | 18 | 4.5 | 0 | alectinib 600 mg BID | 15.8 | true | MSI-H | 2026-03-15T05:35:59.242132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590767 | REC_0009653 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 13.3 | 60 | female | 0 | 6 | 4.6 | 6 | osimertinib 80 mg daily | 12.1 | true | MSS | 2026-03-15T05:35:59.242377+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332873 | REC_0009654 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 15.3 | 85 | female | 0 | 16 | 3.8 | 1 | osimertinib 80 mg daily | 12.1 | false | MSI-H | 2026-03-15T05:35:59.242616+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763147 | REC_0009655 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 5.6 | 64 | female | 1 | 14 | 4.5 | 5 | pembrolizumab 200 mg q3w | 7.4 | true | MSS | 2026-03-15T05:35:59.242861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_287548 | REC_0009656 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 15.2 | 77 | female | 2 | 9 | 7.6 | 3 | osimertinib 80 mg daily | 14.4 | false | MSS | 2026-03-15T05:35:59.243117+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_298613 | REC_0009657 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 15.4 | 73 | female | 1 | 17 | 7.7 | 4 | osimertinib 80 mg daily | 17.8 | false | MSI-H | 2026-03-15T05:35:59.243357+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173470 | REC_0009658 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 13.5 | 72 | female | 2 | 17 | 5.1 | 6 | osimertinib 80 mg daily | 15.1 | false | MSS | 2026-03-15T05:35:59.243597+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_472879 | REC_0009659 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 11.7 | 60 | female | 1 | 14 | 6.4 | 1 | alectinib 600 mg BID | 20 | false | MSS | 2026-03-15T05:35:59.243838+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222554 | REC_0009660 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 16.7 | 67 | female | 1 | 6 | 6.4 | 1 | alectinib 600 mg BID | 18.1 | true | MSI-H | 2026-03-15T05:35:59.244203+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707380 | REC_0009661 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 2.1 | 64 | female | 0 | 61 | 5.9 | 4 | carboplatin + paclitaxel + pembrolizumab | 17.3 | false | MSS | 2026-03-15T05:35:59.244449+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_562050 | REC_0009662 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 16.1 | 73 | male | 1 | 20 | 3.5 | 1 | sotorasib 960 mg daily | 21.8 | false | MSI-H | 2026-03-15T05:35:59.244696+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368388 | REC_0009663 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 10.1 | 56 | female | 1 | 9 | 6.5 | 5 | osimertinib 80 mg daily | 6.3 | false | MSS | 2026-03-15T05:35:59.244936+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_867211 | REC_0009664 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 7.2 | 77 | male | 2 | 44 | 4.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 23.8 | true | MSS | 2026-03-15T05:35:59.245169+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700120 | REC_0009665 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 11.8 | 66 | male | 1 | 14 | 5.4 | 2 | osimertinib 80 mg daily | 19.8 | true | MSI-H | 2026-03-15T05:35:59.245408+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_892151 | REC_0009666 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 2 | 71 | female | 0 | 54 | 5.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 23.3 | false | MSS | 2026-03-15T05:35:59.245636+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_428881 | REC_0009667 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 13.2 | 64 | female | 1 | 16 | 5 | 2 | entrectinib 600 mg daily | 14.1 | false | MSI-H | 2026-03-15T05:35:59.245872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373343 | REC_0009668 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 13.2 | 73 | female | 1 | 16 | 5.8 | 1 | alectinib 600 mg BID | 13.1 | true | MSS | 2026-03-15T05:35:59.246107+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_851712 | REC_0009669 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 3 | 67 | female | 1 | 17 | 6.6 | 4 | osimertinib 80 mg daily | 14.1 | true | MSS | 2026-03-15T05:35:59.246335+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_581087 | REC_0009670 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 13.7 | 64 | male | 0 | 12 | 3.4 | 7 | osimertinib 80 mg daily | 5.7 | false | MSI-H | 2026-03-15T05:35:59.246568+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_364433 | REC_0009671 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 9.4 | 56 | female | 1 | 8 | 6.2 | 6 | entrectinib 600 mg daily | 4.3 | false | MSS | 2026-03-15T05:35:59.246802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378588 | REC_0009672 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 2.4 | 63 | female | 1 | 12 | 3 | 7 | pembrolizumab 200 mg q3w | 15.6 | true | MSS | 2026-03-15T05:35:59.247032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730493 | REC_0009673 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 14.5 | 59 | female | 1 | 15 | 4.5 | 6 | alectinib 600 mg BID | 10.3 | false | MSS | 2026-03-15T05:35:59.247324+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_777749 | REC_0009674 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 18.1 | 70 | female | 2 | 24 | 7 | 3 | entrectinib 600 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:59.247563+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811804 | REC_0009675 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 11.6 | 55 | female | 0 | 7 | 7 | 6 | sotorasib 960 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:59.247797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214639 | REC_0009676 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 7.9 | 83 | female | 2 | 19 | 4.7 | 1 | alectinib 600 mg BID | 12.1 | false | MSS | 2026-03-15T05:35:59.248023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553496 | REC_0009677 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 16.4 | 68 | female | 0 | 14 | 7.6 | 7 | alectinib 600 mg BID | 7.1 | false | MSI-H | 2026-03-15T05:35:59.248322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257794 | REC_0009678 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 8.4 | 64 | female | 0 | 13 | 4.3 | 6 | alectinib 600 mg BID | 17.9 | false | MSS | 2026-03-15T05:35:59.248561+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_220920 | REC_0009679 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 10.6 | 66 | female | 1 | 10 | 7 | 5 | osimertinib 80 mg daily | 10.2 | false | MSS | 2026-03-15T05:35:59.248799+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332414 | REC_0009680 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 5.1 | 74 | female | 2 | 8 | 7.7 | 7 | pembrolizumab 200 mg q3w | 17.9 | false | MSS | 2026-03-15T05:35:59.249026+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_835964 | REC_0009681 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 10.3 | 68 | female | 0 | 12 | 6.9 | 3 | sotorasib 960 mg daily | 19.6 | false | MSI-H | 2026-03-15T05:35:59.249261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150949 | REC_0009682 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 14.8 | 65 | female | 0 | 23 | 4.8 | 6 | entrectinib 600 mg daily | 9.1 | true | MSI-H | 2026-03-15T05:35:59.249498+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997718 | REC_0009683 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 10.8 | 74 | female | 1 | 30 | 6 | 1 | sotorasib 960 mg daily | 7.4 | false | MSS | 2026-03-15T05:35:59.249737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_436243 | REC_0009684 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 19.6 | 64 | female | 0 | 25 | 6 | 5 | sotorasib 960 mg daily | 15.5 | false | MSS | 2026-03-15T05:35:59.249974+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421933 | REC_0009685 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 11 | 9 | 72 | female | 1 | 68 | 7.1 | 7 | carboplatin + paclitaxel + pembrolizumab | 10 | false | MSS | 2026-03-15T05:35:59.250200+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_905031 | REC_0009686 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 31 | 3.5 | 71 | female | 2 | 14 | 5.3 | 2 | pembrolizumab 200 mg q3w | 16.7 | true | MSS | 2026-03-15T05:35:59.250488+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306620 | REC_0009687 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 10.2 | 82 | male | 1 | 4 | 5.9 | 3 | entrectinib 600 mg daily | 14.8 | false | MSI-H | 2026-03-15T05:35:59.250731+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609511 | REC_0009688 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 25 | 12.7 | 56 | female | 0 | 7 | 6.2 | 0 | osimertinib 80 mg daily | 39.9 | true | MSI-H | 2026-03-15T05:35:59.250973+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_912962 | REC_0009689 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 17.3 | 55 | female | 0 | 11 | 5.2 | 2 | pembrolizumab 200 mg q3w | 18.8 | false | MSS | 2026-03-15T05:35:59.251217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321829 | REC_0009690 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 29 | 10.2 | 62 | male | 0 | 9 | 5.4 | 0 | osimertinib 80 mg daily | 24.3 | false | MSS | 2026-03-15T05:35:59.251453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736010 | REC_0009691 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 26 | 7 | 61 | female | 1 | 49 | 5.5 | 2 | pembrolizumab 200 mg q3w | 19 | true | MSS | 2026-03-15T05:35:59.251687+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421841 | REC_0009692 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 27 | 11.2 | 56 | male | 0 | 10 | 5.2 | 0 | osimertinib 80 mg daily | 35.4 | false | MSI-H | 2026-03-15T05:35:59.251923+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_758817 | REC_0009693 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 3.8 | 62 | male | 0 | 62 | 5.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:59.252183+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_716443 | REC_0009694 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 6.7 | 54 | female | 0 | 51 | 3.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.4 | false | MSS | 2026-03-15T05:35:59.252423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_857648 | REC_0009695 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 16.5 | 74 | male | 1 | 9 | 6.8 | 1 | osimertinib 80 mg daily | 23 | false | MSS | 2026-03-15T05:35:59.252672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_303455 | REC_0009696 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 16.1 | 85 | female | 1 | 20 | 6.5 | 1 | sotorasib 960 mg daily | 15.1 | false | MSS | 2026-03-15T05:35:59.252918+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103374 | REC_0009697 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 23 | 13 | 73 | female | 0 | 10 | 5 | 0 | alectinib 600 mg BID | 26.7 | false | MSI-H | 2026-03-15T05:35:59.253193+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_477372 | REC_0009698 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 8.8 | 64 | male | 0 | 10 | 2.8 | 1 | sotorasib 960 mg daily | 13.7 | false | MSS | 2026-03-15T05:35:59.253432+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680221 | REC_0009699 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 11.6 | 45 | female | 0 | 24 | 3.5 | 6 | pembrolizumab 200 mg q3w | 13.3 | false | MSI-H | 2026-03-15T05:35:59.253727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_985406 | REC_0009700 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 6.2 | 72 | female | 1 | 21 | 5.6 | 5 | osimertinib 80 mg daily | 9.7 | true | MSS | 2026-03-15T05:35:59.253970+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.